Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer

Hong Jae Chon, Sun Young Rha, Hyung Soon Park, Sang Joon Shin, Hyo Song Kim, Jae Kyung Roh, Sung Hoon Noh, Hyun Cheol Chung, Hei Cheul Jeung

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: This phase II trial first describes the combination chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) for pretreated advanced gastric cancer (AGC) patients. Methods: Patients who had previously been treated with greater than or equal to one regimen were enrolled. They received S-1 35 mg/m 2 twice daily on days 1-14 and irinotecan 150 mg/m 2 on days 1 and 15, every 4 weeks. The primary endpoint was overall survival (OS). Results: Among the 38 patients enrolled, 18 patients were treated as second line, and the remaining 20 patients were enrolled as third- or fourth line. A total of 208 cycles were administered with the median being four cycles (range 1-16). The median OS was 8.7 months [95% confidence interval (CI) 7.5-10.3], and the median progression-free survival was 6.3 months (95% CI 5.3-7.3). Low serum albumin (<3.5 mg/dL) was an independent adverse prognosticator for survival. Overall response rate was 17% (95% CI 4-30%). The major grade 3/4 toxicities were neutropenia (26%) and diarrhea (18%). Conclusions: Biweekly IRIS showed the moderate activity as salvage treatment in AGC. Considering high neutropenia and gastrointestinal toxicity, patient selection should be warranted; serum albumin may be a predictive factor for treatment decision.

Original languageEnglish
Pages (from-to)991-999
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Volume68
Issue number4
DOIs
Publication statusPublished - 2011 Oct

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer'. Together they form a unique fingerprint.

  • Cite this